Glutamate release is a root cause of acute and delayed neuronal damage in response to hypoxic/ischemic insults. Nevertheless, therapeutics that target the postsynaptic compartment have been disappointing clinically. Here we explored whether presynaptic silencing (muting) of glutamatergic terminals is sufficient to reduce excitotoxic damage resulting from hypoxia and oxygen/glucose deprivation. Our evidence suggests that strong depolarization, previously shown to mute glutamate synapses, protects neurons by a presynaptic mechanism that is sensitive to inhibition of the proteasome. Postsynaptic Ca 2+ rises in response to glutamate application and toxicity in response to exogenous glutamate treatment were unaffected by depolarization preconditioning. These features strongly suggest that reduced glutamate release explains preconditioning protection. We addressed whether hypoxic depolarization itself induces presynaptic silencing, thereby participating in the damage threshold for hypoxic insult. Indeed, we found that the hypoxic insult increased the percentage of mute glutamate synapses in a proteasome-dependent manner. Furthermore, proteasome inhibition exacerbated neuronal loss to mild hypoxia and prevented hypoxia-induced muting. In total our results suggest that presynaptic silencing is an endogenous neuroprotective mechanism that could be exploited to reduce damage from insults involving excess synaptic glutamate release.
Introduction
For decades we have known that glutamate excitotoxicity (Olney et al., 1971) results in damage to neurons following a wide variety of insults including hypoxia, ischemia, seizures (Gidday, 2006; Goldberg and Choi, 1993; Rothman, 1984) , and neuropsychiatric disorders (Olney, 2003; Zorumski and Olney, 1993) . Therapeutic approaches have centered on blocking glutamate receptors and other downstream, postsynaptic targets involved in the excitotoxic cascade. Unfortunately, these approaches have proven disappointing in human studies because of poor efficacy or unacceptable side effects (Gidday, 2006; Moskowitz et al., 2010) . Thus fresh approaches and new basic insights are needed. One alternative might be to study and exploit endogenous homeostatic synaptic mechanisms as strategies. By augmenting endogenous pathways of adaptive synaptic plasticity, such strategies might circumvent some of the problems that have arisen with previous interventions.
We have been studying a form of persistent presynaptic plasticity involving depression of glutamate vesicle availability in hippocampal neurons. This depression is characterized by presynaptic silencing, or muting, that outlives the inducing stimulus. Muting is induced at glutamate, but not γ-aminobutyric acid (GABA), synapses by strong depolarization (Moulder et al., 2004) . It reverses over several hours (Moulder et al., 2008) and is characterized by involvement of inhibitory G-protein signaling (Crawford et al., 2011) and the ubiquitin/proteasome system (UPS) (Jiang et al., 2010) .
Two issues relevant to excitotoxic pathophysiology emerge from our previous observations. First, because the source of glutamate during excitotoxic insults may not be purely synaptic (Rossi et al., 2000) , it is unclear whether presynaptic interventions, such as induction of presynaptic muting, are effective neuroprotectants. Second, because presynaptic silencing has been induced only under controlled experimental conditions, it is unclear whether depolarizing insults such as hypoxia can induce muting rapidly and strongly enough to provide endogenous neuroprotection. If so, muting may normally help set the threshold for damage during insults. Support for these two ideas would help establish the plausibility of augmentation of presynaptic muting as a neuroprotective intervention and would offer new basic insights into the roles of synaptic plasticity in nervous system function and dysfunction.
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